BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 19766963)

  • 1. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.
    Bahcecioglu IH; Yalniz M; Ataseven H; Ilhan N; Ozercan IH; Seckin D; Sahin K
    Hepatogastroenterology; 2005; 52(65):1549-53. PubMed ID: 16201116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination and clinical significance of tissue inhibitors of metalloproteinase-1 and -2 in serum of children with nonalcoholic fatty liver disease].
    Li YW; Zhu CL; Gao RT; Pan JH
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jun; 12(6):455-8. PubMed ID: 20540856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Fierbinteanu-Braticevici C; Baicus C; Tribus L; Papacocea R
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):153-9. PubMed ID: 21725512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
    Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).
    Sasaki N; Ueno T; Morita Y; Nagata E; Sata M
    Hepatogastroenterology; 2006; 53(71):678-81. PubMed ID: 17086867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease.
    Lieber CS; Weiss DG; Paronetto F;
    Alcohol Clin Exp Res; 2008 Jun; 32(6):1031-9. PubMed ID: 18422837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relationship of serum metalloproteinase with the severity of liver fibrosis and inflammation].
    Yin SS; Li XM; Wang BE; Wang TL; Jia JD; Qian LX
    Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):666-8. PubMed ID: 15623375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Suzuki A; Angulo P; Lymp J; Li D; Satomura S; Lindor K
    Liver Int; 2005 Aug; 25(4):779-86. PubMed ID: 15998429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated?
    Helling TS; Helzberg JH; Nachnani JS; Gurram K
    Surg Obes Relat Dis; 2008; 4(5):612-7. PubMed ID: 18226970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.
    Sanvisens A; Serra I; Tural C; Tor J; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Muga R
    J Viral Hepat; 2009 Jul; 16(7):513-8. PubMed ID: 19200132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.
    Lydatakis H; Hager IP; Kostadelou E; Mpousmpoulas S; Pappas S; Diamantis I
    Liver Int; 2006 Sep; 26(7):864-71. PubMed ID: 16911470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.
    Boza C; Riquelme A; IbaƱez L; Duarte I; Norero E; Viviani P; Soza A; Fernandez JI; Raddatz A; Guzman S; Arrese M
    Obes Surg; 2005 Sep; 15(8):1148-53. PubMed ID: 16197788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
    Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
    Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.